Related Experiment Video
Updated: Aug 27, 2025
09:04
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
632
[Tumor Immunogenicity and Immune Checkpoint Inhibitors]
Masao Nakajima1, Ryoichi Tsunedomi, Yoshitaro Shindo
1Dept. of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|September 26, 2022
Summary
Cancer immunotherapy using immune checkpoint inhibitors (ICIs) shows limited response rates. This review explores enhancing tumor immunogenicity to convert "cold tumors" into "hot tumors" for better treatment outcomes, introducing novel peptide vaccination therapy.
Area of Science:
- Oncology
- Immunology
- Cancer Therapy
Background:
- Immune checkpoint inhibitors (ICIs) represent a significant advancement in cancer treatment.
- However, only about 20% of patients respond to ICIs, with resistance often linked to
- cold tumors
- characterized by low immunogenicity.
Purpose of the Study:
- To review the intricate relationship between tumor immunogenicity and ICI efficacy.
- To explore therapeutic strategies aimed at increasing tumor immunogenicity.
- To introduce novel cancer peptide vaccination as a potential treatment modality.
Main Methods:
- Literature review on tumor immunogenicity and ICI response.
- Analysis of therapeutic approaches to enhance tumor immunogenicity.
- Presentation of preliminary research on cancer peptide vaccination.
Main Results:
- Cold tumors exhibit low immunogenicity, contributing to resistance against ICIs.
- Strategies to enhance tumor immunogenicity are crucial for improving ICI effectiveness.
- Novel cancer peptide vaccination therapy shows promise in converting cold tumors to hot.
Conclusions:
- Overcoming ICI resistance requires enhancing tumor immunogenicity.
- Targeting tumor immunogenicity is a key area for developing more effective cancer therapies.
- Cancer peptide vaccination offers a promising avenue for improving patient outcomes in immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
643
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
643
02:17The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
01:30Cancer Vaccines
493
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
493